US.INCY · Incyte

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.4,
      "details": {
        "atrPct": 2.6453579243513596,
        "turnoverUsdM": 71.48626156,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.INCY",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 121.19,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 0.5,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 5.3,
      "take_profit_price": 135.0347,
      "target_multiplier": 1.9,
      "technical_strength": 1.65,
      "take_profit_percent": 5.5
    },
    "positionPoints": 1.4,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.290715848702719,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 74.3,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 63.3,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 11
  },
  "market": {
    "ma20": 122.9905,
    "ma50": 116.6018,
    "close": 127.96,
    "prevClose": 127.81,
    "avgVolume20": 1778423,
    "volumeRatio": 0.31,
    "changePercent": 0.12
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 11,
    "details": {
      "ret_5d": 0.03611336032388657,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 11,
      "vcp_bonus": 0,
      "vol_ratio": 0.29606796206546593,
      "ret_points": 8,
      "vol_points": 0,
      "range_ratio": 0.5445640837221725,
      "volat_points": 0,
      "day_range_pct": 0.018052516411378575,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 74.3,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 100,
        "contribution": 5
      },
      {
        "raw": 14.8,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 74,
        "contribution": 14.8
      },
      {
        "raw": 8,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 53.33,
        "contribution": 8
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.6,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 66,
        "contribution": 6.6
      },
      {
        "raw": 20.9,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 69.67,
        "contribution": 20.9
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 63.3,
    "details": [
      "基本面分析總分: 5/5分",
      "資金流分析總分: 14.8/20分",
      "市場環境分析總分: 8/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.6/10分",
      "技術信號分析總分: 20.9/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 5,
      "資金流": 14.8,
      "市場環境": 8,
      "情緒分析": 6,
      "技術信號": 20.9,
      "風險管理": 6.6
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.5,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0.75,
          "turnoverUsdM": 71.48626156,
          "volumePoints": 0.5,
          "revenuePoints": 0.75,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "良好",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 3.2,
          "obvPoints": 4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.INCY",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 15.13
            }
          },
          "trend": {
            "score": 1.7999999999999998,
            "details": {
              "qqq": {
                "ma20": 710.3985018500001,
                "ma50": 713.2256020399999,
                "name": "QQQ",
                "close": 706.32001,
                "points": 0.4
              },
              "spy": {
                "ma20": 763.5459993000001,
                "ma50": 752.2638036,
                "name": "SPY",
                "close": 763.46997,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.6453579243513596,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 1.7999999999999998
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141236905,
                "url": "https://finnhub.io/api/news?id=e2562bc71c755ab8798ab74f17a3e76faa67dfed36a065bc7c2710aa081b5e0f",
                "image": "https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "Incyte (INCY) shows strong growth momentum with a clean technical setup, combining high earnings growth, positive ratings, and a breakout opportunity.",
                "category": "company",
                "datetime": 1786956062,
                "headline": "Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup"
              },
              {
                "id": 141212325,
                "url": "https://finnhub.io/api/news?id=eab69f161a62ae7c0a6bc4f8c5d70d30ef1c4172ba9ca6b60510de889428f545",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "On July 20, Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Incyte Corporation (NASDAQ:INCY) announced a global collaboration and licensing deal to develop a subcutaneous formulation of Incyte’s INCA033989. The first-in-class monoclonal antibody targets mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms. By utilizing Halozyme’s proprietary ENHANZE drug delivery technology, INCY aims to create a more convenient dosing regimen for patients. […]",
                "category": "company",
                "datetime": 1786665884,
                "headline": "Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?"
              },
              {
                "id": 141124378,
                "url": "https://finnhub.io/api/news?id=2e9cdc845599ec8de38ca915bc2ee2ada5fb327446645dc572f0ce9a833e59b9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "REGN vs. INCY: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1785944402,
                "headline": "REGN or INCY: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 141089558,
                "url": "https://finnhub.io/api/news?id=d193e1a9da786dba927302825e1ac4e436b47d2a4ef395a053f2eb026d40287d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (INCY) is back in focus after the European Commission approved Opzelura cream for moderate atopic dermatitis in certain adults, shortly after the company reported second quarter results and raised full year sales guidance. See our latest analysis for Incyte. The recent European approval for Opzelura and the stronger second quarter results come after a period of firm momentum in Incyte’s stock, with a 90 day share price return of 23.33% and a 1 year total shareholder return of...",
                "category": "company",
                "datetime": 1785618581,
                "headline": "Incyte (INCY) Won EU Approval For Opzelura, Has The Market Already Priced It In?"
              },
              {
                "id": 141089559,
                "url": "https://finnhub.io/api/news?id=66ee3d96f932a33253226f3002e3e870617e598368af7691a991672344718603",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte stock has delivered a strong run over the last three years, yet the broader valuation checks suggest it may no longer stand out as a clear bargain at current levels. Incyte has returned 87.8% over the past three years, which puts fresh focus on whether recent gains already reflect much of the good news. Recent approvals for Opzelura in atopic dermatitis and new partnership activity can support confidence in future revenue, while execution risk around expanding treatments and...",
                "category": "company",
                "datetime": 1785614991,
                "headline": "Incyte (INCY) Stock Trades Reasonable On Earnings While Returns Look Strong"
              },
              {
                "id": 141089087,
                "url": "https://finnhub.io/api/news?id=4cafa0c0c576492af58b5a037d3e4d674d60091cc75d218a9fff9032cba9f660",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "In July 2026, Incyte received European Commission approval for Opzelura (ruxolitinib) cream to treat moderate atopic dermatitis in adults who do not respond adequately to, or cannot use, topical corticosteroids and calcineurin inhibitors, supported by positive Phase 3 data showing improved symptoms, quality of life and tolerability. This second European indication for Opzelura, alongside strong Phase 3b TRuE-AD4 outcomes, highlights Incyte’s growing dermatology franchise and its ability to...",
                "category": "company",
                "datetime": 1785611472,
                "headline": "European Opzelura Approval in Atopic Dermatitis Could Be A Game Changer For Incyte (INCY)"
              },
              {
                "id": 141088479,
                "url": "https://finnhub.io/api/news?id=817f6fcd57e34aec0ab49f7cd5b44a5e25bd5579e73d8284a3f8cfe53577ab60",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "European Commission approves Opzelura (ruxolitinib) cream as the first steroid free topical JAK inhibitor for adults with moderate atopic dermatitis in the EU. Decision is based on Phase 3b TRuE AD4 data in adult patients with mild to moderate atopic dermatitis. Approval expands Opzelura's use in Europe and adds a new dermatology revenue opportunity for Incyte. For investors following Incyte, ticker NasdaqGS:INCY, this EU approval adds a fresh piece of news around its dermatology efforts...",
                "category": "company",
                "datetime": 1785604078,
                "headline": "Incyte (INCY) Wins EU Approval For Opzelura In Adult Moderate Atopic Dermatitis"
              },
              {
                "id": 141046508,
                "url": "https://finnhub.io/api/news?id=6f63228fc5636768c7177d6706a78488fb4357da7446b67f6d5006217d3645c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte Corp (INCY) reports a 38% increase in total revenue, raises full-year guidance, and highlights significant advancements in its diverse product pipeline.",
                "category": "company",
                "datetime": 1785265310,
                "headline": "Incyte Corp (INCY) Q2 2026 Earnings Call Highlights: Robust Revenue Growth and Strategic ..."
              }
            ],
            "raw_source": [
              {
                "id": 141300403,
                "url": "https://finnhub.io/api/news?id=423ff622523781f562142ed7b0b7d87cfe74dfb95cf04deb4b282bc564269b75",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2286515404/image_2286515404.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Prelude Therapeutics has rebounded 500% in 12 months after a $60M option deal with Incyte for its JAK2 inhibitor program. Read why PRLD stock is a Hold.",
                "category": "company",
                "datetime": 1787464368,
                "headline": "Prelude Therapeutics: A Prognosis After Year-Long Rally"
              },
              {
                "id": 141291858,
                "url": "https://finnhub.io/api/news?id=8ba28b3ef62591be53bd1267edb3588386fb93f48e84c11e7fd4e7edc819225a",
                "image": "",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "",
                "category": "company",
                "datetime": 1787390100,
                "headline": "TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors"
              },
              {
                "id": 141274492,
                "url": "https://finnhub.io/api/news?id=16bd98dd0d2cd72220a3471604976fb19d885131090151f26e69bac8333e7d5e",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.29% on an annualized basis producing an average annual return of 17.52%. Currently, Incyte has a market capitalization of $25.75 billion.",
                "category": "company",
                "datetime": 1787254247,
                "headline": "Here’s How Much You Would Have Made Owning Incyte Stock In The Last 20 Years"
              },
              {
                "id": 141274493,
                "url": "https://finnhub.io/api/news?id=baf58b8a3a3b06983aa4287c99be7c1994398570b783f8bed504eb6913278b8f",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Canaccord Genuity  analyst John Newman   initiates coverage on Incyte (NASDAQ:INCY) with a Buy rating and announces Price Target of $152.",
                "category": "company",
                "datetime": 1787240668,
                "headline": "Canaccord Genuity Initiates Coverage On Incyte with Buy Rating, Announces Price Target of $152"
              },
              {
                "id": 141279013,
                "url": "https://finnhub.io/api/news?id=a8bd927ed75c88b5492ec4b6332f4c7ae2352eb289871e0eafb613dfc6f6ee2e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Pre-Market Stock Futures: Futures are trading lower after a wild day on Wall Street, as stocks took off after Treasury Secretary Bessent announced the Treasury would double its current bond buyback, targeting 10- to 20-year and 20- to 30-year maturities. That sparked an initial big rally, which tapered by the close; still, all of the ... Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Analog Devices, Crown Castle, ebay, EPR Properties, Etsy, Merck & Co., Shopify, TJX Compan",
                "category": "company",
                "datetime": 1787230899,
                "headline": "Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Analog Devices, Crown Castle, ebay, EPR Properties, Etsy, Merck & Co., Shopify, TJX Companies, and More"
              },
              {
                "id": 141261028,
                "url": "https://finnhub.io/api/news?id=5b54ec56dfde684c05d3723c87da63c116166a04b8bff3d3ea948663950358c1",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2280454849/image_2280454849.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Tempus AI remains a strong buy, driven by its unique flywheel business model and recent validation of its technology via the Personalis acquisition. Learn more about TEM stock here.",
                "category": "company",
                "datetime": 1787212800,
                "headline": "Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine Advance"
              },
              {
                "id": 141263185,
                "url": "https://finnhub.io/api/news?id=4cd5ae836be6f6418eee00221bbef18dcadafba15c22cac06eb43294a6ea0940",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "HC Wainwright & Co.  analyst Mitchell S. Kapoor   reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $150 price target.",
                "category": "company",
                "datetime": 1787211661,
                "headline": "HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $150 Price Target"
              },
              {
                "id": 141275618,
                "url": "https://finnhub.io/api/news?id=2e14a3663cced0c66c160a821e086b59e581ab07ad28e57a62b87130bcadaac1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Wolfe Research identified seven stocks combining strong earnings, rapid sales growth, and positive momentum in a tough market.",
                "category": "company",
                "datetime": 1787208360,
                "headline": "7 Growth Stocks Holding Up in a Tough Market"
              },
              {
                "id": 141255594,
                "url": "https://finnhub.io/api/news?id=3be879eac62e53b8c7ea7ac790ed318cfb5727f57f7db7b32c3dc2c47c2f3ada",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155151969/image_155151969.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Silence Therapeutics rises on trial results and funding updates; Read on to see Divesiran’s outlook vs. Takeda’s rusfertide competition and analyst views.",
                "category": "company",
                "datetime": 1787152436,
                "headline": "Silence Therapeutics: Making Some Recent Noise"
              },
              {
                "id": 141284452,
                "url": "https://finnhub.io/api/news?id=0eaec1ca73de100ad8399049583950b5de8402dda4c0e4e30e422d646ef4fae7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "While Incyte has outperformed the broader market over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.",
                "category": "company",
                "datetime": 1787061045,
                "headline": "Incyte Stock: Is Wall Street Bullish or Bearish?"
              },
              {
                "id": 141238981,
                "url": "https://finnhub.io/api/news?id=46e00c10dc1a4ea0aee1e64048bfd66c65f06433ec62da4433666def96ea0b23",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Piper Sandler  analyst Allison Bratzel   maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $110 to $130.",
                "category": "company",
                "datetime": 1786968688,
                "headline": "Piper Sandler Maintains Overweight on Incyte, Raises Price Target to $130"
              },
              {
                "id": 141236905,
                "url": "https://finnhub.io/api/news?id=e2562bc71c755ab8798ab74f17a3e76faa67dfed36a065bc7c2710aa081b5e0f",
                "image": "https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "Incyte (INCY) shows strong growth momentum with a clean technical setup, combining high earnings growth, positive ratings, and a breakout opportunity.",
                "category": "company",
                "datetime": 1786956062,
                "headline": "Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup"
              },
              {
                "id": 141231125,
                "url": "https://finnhub.io/api/news?id=20166a2b2acd2263cfdbcc99fc419c59e514054bea615fc73fdbae8d84095aeb",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445262091/image_1445262091.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Healthcare sector valuation check: equipment undervalued, providers near baseline, pharma/biotech overvalued. Learn more about IHF ETF here.",
                "category": "company",
                "datetime": 1786867596,
                "headline": "IHF: Healthcare Dashboard For August"
              },
              {
                "id": 141212325,
                "url": "https://finnhub.io/api/news?id=eab69f161a62ae7c0a6bc4f8c5d70d30ef1c4172ba9ca6b60510de889428f545",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "On July 20, Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Incyte Corporation (NASDAQ:INCY) announced a global collaboration and licensing deal to develop a subcutaneous formulation of Incyte’s INCA033989. The first-in-class monoclonal antibody targets mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms. By utilizing Halozyme’s proprietary ENHANZE drug delivery technology, INCY aims to create a more convenient dosing regimen for patients. […]",
                "category": "company",
                "datetime": 1786665884,
                "headline": "Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?"
              },
              {
                "id": 141202549,
                "url": "https://finnhub.io/api/news?id=4fe7c7f9666f23d0227a64f76343e75b8c58582e476184aa7cb8a1856e19ab65",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Biopharmaceutical company Incyte Corporation (INCY) gets Big Money support to gain 23% so far in 2026.",
                "category": "company",
                "datetime": 1786552729,
                "headline": "Incyte Sales Growth Drives Share Price Gains"
              },
              {
                "id": 141152614,
                "url": "https://finnhub.io/api/news?id=9d919d98638ab10c58b0089512804d868fcbadaeac464c88271744e371027ef4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "WILMINGTON, Del., August 07, 2026--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
                "category": "company",
                "datetime": 1786134600,
                "headline": "Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"
              },
              {
                "id": 141137504,
                "url": "https://finnhub.io/api/news?id=5ba2cc11a9ecb49edc66612183fe45868379495b15bc40aff39523368206fff5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.",
                "category": "company",
                "datetime": 1786029660,
                "headline": "Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised"
              },
              {
                "id": 141124378,
                "url": "https://finnhub.io/api/news?id=2e9cdc845599ec8de38ca915bc2ee2ada5fb327446645dc572f0ce9a833e59b9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "REGN vs. INCY: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1785944402,
                "headline": "REGN or INCY: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 141125130,
                "url": "https://finnhub.io/api/news?id=ec67b5cb9214019a7c398a6f91533f609baf347be1299b6c7d6517db16aaed99",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Mizuho  analyst Salim Syed   maintains Incyte (NASDAQ:INCY) with a Outperform and raises the price target from $121 to $137.",
                "category": "company",
                "datetime": 1785852726,
                "headline": "Mizuho Maintains Outperform on Incyte, Raises Price Target to $137"
              },
              {
                "id": 141099326,
                "url": "https://finnhub.io/api/news?id=cc2662e857815e4ce5bff63b03718501328f075fffcc39c614651be14387b757",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2156417320/image_2156417320.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "AbbVie Inc. stock fell 6.2% after a 52-week high despite strong Q2 earnings; Rinvoq and Elahere sales surged. Click for this ABBV earnings udpate.",
                "category": "company",
                "datetime": 1785751531,
                "headline": "AbbVie: Strong Q2 And New Catalysts Keep Me Bullish"
              },
              {
                "id": 141099586,
                "url": "https://finnhub.io/api/news?id=2236694b532821ccd17ec78e8aa739f376a9517d1f738f8e47c88a2f4f048e45",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/03/Warsaw--Poland--31-July-2024--Wola-Busin.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Top Wall Street analysts changed their outlook on top names. Barclays raised DAR's target to $65, BTIG boosted SNOW's target to $340, and JP Morgan upgraded LYB to Overweight.",
                "category": "company",
                "datetime": 1785744979,
                "headline": "Snowflake To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday"
              },
              {
                "id": 141103928,
                "url": "https://finnhub.io/api/news?id=c2efedbdc50b89967269d5ad051b03083f0c004678077351407ad8b011b50cca",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Leerink Partners  analyst Andrew Berens   maintains Incyte (NASDAQ:INCY) with a Outperform and raises the price target from $131 to $155.",
                "category": "company",
                "datetime": 1785739354,
                "headline": "Leerink Partners Maintains Outperform on Incyte, Raises Price Target to $155"
              },
              {
                "id": 141103930,
                "url": "https://finnhub.io/api/news?id=485fe4314e98cd1700421551c15cbb80275c7ebc3755e5fdc7bff0b5ada4863f",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "MinjuvI (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen listed on the Pharmaceutical Benefits Scheme",
                "category": "company",
                "datetime": 1785724582,
                "headline": "Reported Sunday, Incyte's Minjuvi Plus Rituximab And Lenalidomide Now PBS-Funded In Australia, First New R/R Follicular Lymphoma Therapy Reimbursed In Nine Years"
              },
              {
                "id": 141089558,
                "url": "https://finnhub.io/api/news?id=d193e1a9da786dba927302825e1ac4e436b47d2a4ef395a053f2eb026d40287d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (INCY) is back in focus after the European Commission approved Opzelura cream for moderate atopic dermatitis in certain adults, shortly after the company reported second quarter results and raised full year sales guidance. See our latest analysis for Incyte. The recent European approval for Opzelura and the stronger second quarter results come after a period of firm momentum in Incyte’s stock, with a 90 day share price return of 23.33% and a 1 year total shareholder return of...",
                "category": "company",
                "datetime": 1785618581,
                "headline": "Incyte (INCY) Won EU Approval For Opzelura, Has The Market Already Priced It In?"
              },
              {
                "id": 141089559,
                "url": "https://finnhub.io/api/news?id=66ee3d96f932a33253226f3002e3e870617e598368af7691a991672344718603",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte stock has delivered a strong run over the last three years, yet the broader valuation checks suggest it may no longer stand out as a clear bargain at current levels. Incyte has returned 87.8% over the past three years, which puts fresh focus on whether recent gains already reflect much of the good news. Recent approvals for Opzelura in atopic dermatitis and new partnership activity can support confidence in future revenue, while execution risk around expanding treatments and...",
                "category": "company",
                "datetime": 1785614991,
                "headline": "Incyte (INCY) Stock Trades Reasonable On Earnings While Returns Look Strong"
              },
              {
                "id": 141089087,
                "url": "https://finnhub.io/api/news?id=4cafa0c0c576492af58b5a037d3e4d674d60091cc75d218a9fff9032cba9f660",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "In July 2026, Incyte received European Commission approval for Opzelura (ruxolitinib) cream to treat moderate atopic dermatitis in adults who do not respond adequately to, or cannot use, topical corticosteroids and calcineurin inhibitors, supported by positive Phase 3 data showing improved symptoms, quality of life and tolerability. This second European indication for Opzelura, alongside strong Phase 3b TRuE-AD4 outcomes, highlights Incyte’s growing dermatology franchise and its ability to...",
                "category": "company",
                "datetime": 1785611472,
                "headline": "European Opzelura Approval in Atopic Dermatitis Could Be A Game Changer For Incyte (INCY)"
              },
              {
                "id": 141088479,
                "url": "https://finnhub.io/api/news?id=817f6fcd57e34aec0ab49f7cd5b44a5e25bd5579e73d8284a3f8cfe53577ab60",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "European Commission approves Opzelura (ruxolitinib) cream as the first steroid free topical JAK inhibitor for adults with moderate atopic dermatitis in the EU. Decision is based on Phase 3b TRuE AD4 data in adult patients with mild to moderate atopic dermatitis. Approval expands Opzelura's use in Europe and adds a new dermatology revenue opportunity for Incyte. For investors following Incyte, ticker NasdaqGS:INCY, this EU approval adds a fresh piece of news around its dermatology efforts...",
                "category": "company",
                "datetime": 1785604078,
                "headline": "Incyte (INCY) Wins EU Approval For Opzelura In Adult Moderate Atopic Dermatitis"
              },
              {
                "id": 141086380,
                "url": "https://finnhub.io/api/news?id=a1b1742c992e86e8d9ed9e79579e23316e166304fcfe86f582799192885bc109",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.",
                "category": "company",
                "datetime": 1785571917,
                "headline": "1 Unpopular Stock That Deserves Some Love and 2 Facing Headwinds"
              },
              {
                "id": 141056000,
                "url": "https://finnhub.io/api/news?id=25bcacd240f3bfeeac2755d895eda5e1df2a34a1738e86b8bb28e50d7b71921a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "The European Commission on Wednesday approved Incyte’s Opzelura cream as the first steroid-free topical treatment of its kind for adults with moderate eczema who do not get enough relief from standard creams.",
                "category": "company",
                "datetime": 1785345731,
                "headline": "Incyte Shares Retreat After Best Day In A Year Despite Opzelura EU Nod"
              },
              {
                "id": 141057549,
                "url": "https://finnhub.io/api/news?id=74e2a18e2341a38b90ab247eb729d4ca76f6125ef10ac31a2524925b0e83eec3",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "RBC Capital  analyst Brian Abrahams   maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $99 to $109.",
                "category": "company",
                "datetime": 1785332115,
                "headline": "RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $109"
              },
              {
                "id": 141057550,
                "url": "https://finnhub.io/api/news?id=40386d9cb4aac281a6b0481ca34deb27152a95af696e43543d3343140b79a456",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/29/Konskie--Poland---December-08--2024-Incy.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Incyte Corp. (INCY) reported strong Q2 results, raised full-year sales guidance. CEO cites sales growth, pipeline progress, and business development. Analysts maintain buy ratings with price target increases.",
                "category": "company",
                "datetime": 1785322406,
                "headline": "Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results"
              },
              {
                "id": 141057551,
                "url": "https://finnhub.io/api/news?id=bc5ca8c81baad7c9f72efd5d2ea26272d756b81ce616c2718a93d4e8af4c07bc",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Guggenheim   maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $136 to $150.",
                "category": "company",
                "datetime": 1785320483,
                "headline": "Guggenheim Maintains Buy on Incyte, Raises Price Target to $150"
              },
              {
                "id": 141052276,
                "url": "https://finnhub.io/api/news?id=1a077f383181680361593f4fc0cdfe88a9cc78b10e55fc46662e3e357a704820",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "WILMINGTON, Del., July 29, 2026--Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the EU for Adults with Moderate Atopic Dermatitis",
                "category": "company",
                "datetime": 1785319200,
                "headline": "Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis"
              },
              {
                "id": 141057552,
                "url": "https://finnhub.io/api/news?id=5c418c9628fe19002024d6653630d9b9fee4635bde2599fcce60253b83268ed3",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "BMO Capital  analyst Evan Seigerman   maintains Incyte (NASDAQ:INCY) with a Market Perform and raises the price target from $112 to $130.",
                "category": "company",
                "datetime": 1785318946,
                "headline": "BMO Capital Maintains Market Perform on Incyte, Raises Price Target to $130"
              },
              {
                "id": 141053819,
                "url": "https://finnhub.io/api/news?id=d2c922f03b1f56364c6cb0efc7927b30fcba8881b67cae6e586801e9d792f6b8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/29/Healthcare-stocks.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "RSI warning: 3 overbought health care stocks could be flashing a real warning to investors with high momentum trading preferences",
                "category": "company",
                "datetime": 1785314722,
                "headline": "Top 3 Health Care Stocks That May Implode This Month"
              },
              {
                "id": 141057554,
                "url": "https://finnhub.io/api/news?id=f173421e6fdb09349bc9b98244ae8f6da6a4f51f094f121839ef819f0bdc7f4a",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Barclays  analyst Etzer Darout   maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $134 to $139.",
                "category": "company",
                "datetime": 1785313264,
                "headline": "Barclays Maintains Overweight on Incyte, Raises Price Target to $139"
              },
              {
                "id": 141057555,
                "url": "https://finnhub.io/api/news?id=15490808f6c716b8670ec8e4a3ac083f03234778ad32f16a672785d1ef10aeb7",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "HC Wainwright & Co.  analyst Mitchell S. Kapoor   maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $140 to $150.",
                "category": "company",
                "datetime": 1785306378,
                "headline": "HC Wainwright & Co. Maintains Buy on Incyte, Raises Price Target to $150"
              },
              {
                "id": 141057556,
                "url": "https://finnhub.io/api/news?id=dd8bfd44f7f4c71f85276aabd63a2477ae821d094b6f0e3d8cd4a88bf11d6197",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "The European Commission approval is based on Phase 3b TRuE‑AD4 data which demonstrated that Opzelura® (ruxolitinib) cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment",
                "category": "company",
                "datetime": 1785304963,
                "headline": "Incyte Says EC Approves Opzelura Cream For Treatment Of Moderate Atopic Dermatitis In Adult Patients"
              },
              {
                "id": 141046067,
                "url": "https://finnhub.io/api/news?id=28852786028f830f8c93415f5e5497f7948584b12d1d51d853db9c580c37e955",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session.",
                "category": "company",
                "datetime": 1785265501,
                "headline": "Exploring the top movers within the S&P500 index during today's session."
              },
              {
                "id": 141046508,
                "url": "https://finnhub.io/api/news?id=6f63228fc5636768c7177d6706a78488fb4357da7446b67f6d5006217d3645c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte Corp (INCY) reports a 38% increase in total revenue, raises full-year guidance, and highlights significant advancements in its diverse product pipeline.",
                "category": "company",
                "datetime": 1785265310,
                "headline": "Incyte Corp (INCY) Q2 2026 Earnings Call Highlights: Robust Revenue Growth and Strategic ..."
              },
              {
                "id": 141044671,
                "url": "https://finnhub.io/api/news?id=60d82d912a0cbbf84300ba4e349dd2be3cc82511f788156598ee6f9cfa8ab719",
                "image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below.",
                "category": "company",
                "datetime": 1785258300,
                "headline": "Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below."
              },
              {
                "id": 141045188,
                "url": "https://finnhub.io/api/news?id=9b51439141c29da15f6773f0c3e11b7989e81beaf05eadbc1aee88f09c1c18eb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.",
                "category": "company",
                "datetime": 1785256800,
                "headline": "INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised"
              },
              {
                "id": 141048636,
                "url": "https://finnhub.io/api/news?id=108957862ddf2373a16785e6688d3ad7e0cb2a9cd5b6003f083b48a5bf45f5e1",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/28/Konskie--Poland---December-08--2024-Incy.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Incyte (INCY) Q2 earnings beat estimates with $1.67B revenue, $3.09 EPS. Full-year sales guidance raised. Shares rally to new 52-week high.",
                "category": "company",
                "datetime": 1785251422,
                "headline": "Incyte Says It's No Longer A One-Drug Story"
              },
              {
                "id": 141045820,
                "url": "https://finnhub.io/api/news?id=6a737a4ae55d24ee85b70d55e05108fe48c0483ee293c4c3449d86ca61ec7390",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "2026-07-28. The following slide deck was published by Incyte Corporation in conjunction with their 2026 Q2 earnings call.",
                "category": "company",
                "datetime": 1785249140,
                "headline": "Incyte Corporation 2026 Q2 - Results - Earnings Call Presentation"
              },
              {
                "id": 141044113,
                "url": "https://finnhub.io/api/news?id=525ea22bfc0aacfce1da10e0d3444dc997e7bc6a9a938e2bf465d99100229ba9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (NASDAQ:INCY) reported second-quarter 2026 net product sales of $1.49 billion, up 40% from a year earlier, supported by demand growth across its marketed portfolio and a one-time non-cash benefit tied to the resolution of a CMS matter involving OPZELURA. Excluding the $246 million one-time b",
                "category": "company",
                "datetime": 1785247454,
                "headline": "Incyte Q2 Earnings Call Highlights"
              },
              {
                "id": 141044114,
                "url": "https://finnhub.io/api/news?id=12a76a839b9588cb7b135e7669983aa7815af3ca9ca2dbfe5fcfa664b6ef1426",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
                "category": "company",
                "datetime": 1785245406,
                "headline": "Compared to Estimates, Incyte (INCY) Q2 Earnings: A Look at Key Metrics"
              },
              {
                "id": 141042794,
                "url": "https://finnhub.io/api/news?id=fbd9cd328e5d6e2a42fcc9224756b806eabc2ce57cecc5da3f7d9c4db3a3e37e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (NASDAQ:INCY) reported better-than-expected second-quarter earnings and revenue on Tuesday, although its shares edged lower in pre-market trading after the company issued full-year sales guidance that came in below analysts’ expectations. The biotechnology group delivered strong growth across its commercial portfolio, supported by higher sales from several key products and continued pipeline progress.",
                "category": "company",
                "datetime": 1785245376,
                "headline": "Incyte Tops Second-Quarter Expectations but Shares Slip on Lower Revenue Outlook"
              },
              {
                "id": 141042029,
                "url": "https://finnhub.io/api/news?id=c96d09c019061ce7d6feed85e21a0c0f1efc7c1b939fc4a7215f66194fd03c5a",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_16_065e226ebd.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "Incyte beat Q2 estimates but slashed full-year guidance and raised expenses on a $1.27B acquisition, sending shares down 31% pre-market.",
                "category": "company",
                "datetime": 1785241400,
                "headline": "Incyte (NASDAQ:INCY): High Growth Stock Slides on Q2 Beat but Steep Guidance Cut"
              },
              {
                "id": 141044416,
                "url": "https://finnhub.io/api/news?id=0d4f33d7e5de25a063c9dd5083916e021be4ec9699b53a15cb53d71306169487",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Incyte Corporation (INCY) Q2 2026 Earnings Call July 28, 2026 8:00 AM EDTCompany ParticipantsAlexis Smith - VP & Head of Investor RelationsWilliam Meury...",
                "category": "company",
                "datetime": 1785241392,
                "headline": "Incyte Corporation (INCY) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141042795,
                "url": "https://finnhub.io/api/news?id=3fcb7f376b8aeff1d961740a2084bb1f9106c89c8c86847feed2af8c200c0c8c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (INCY) delivered earnings and revenue surprises of +54.50% and +14.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785240902,
                "headline": "Incyte (INCY) Q2 Earnings and Revenues Top Estimates"
              },
              {
                "id": 141041896,
                "url": "https://finnhub.io/api/news?id=deb542f41aa7f434c46038cc10d4ee4c66e9da2a1fdb0bb664275f2f273c979d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 37.7% year on year to $1.67 billion. On the other hand, the company’s full-year revenue guidance of $5.20 billion at the midpoint came in 9.2% below analysts’ estimates. Its non-GAAP profit of $3.09 per share was 43.9% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785238648,
                "headline": "Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q2 CY2026 But Full-Year Sales Guidance Misses Expectations Significantly"
              },
              {
                "id": 141048637,
                "url": "https://finnhub.io/api/news?id=fca5e3f6a42f39cc70236eb123ad64a4acd4353b60877406ffeff2a86ed0df57",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "In a new SEC filing on July 27, it was unveiled that Heeson, EVP at Incyte (NASDAQ:INCY), acquired stock options for 15,423 shares.\nWhat Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on",
                "category": "company",
                "datetime": 1785236445,
                "headline": "A Noteworthy Decision By Lee Heeson As Acquires $130K In Incyte Stock Options"
              },
              {
                "id": 141048638,
                "url": "https://finnhub.io/api/news?id=021975f7161fbfbaa830a159bef61b90420ef6b1ff29263b4995686d0d8bec97",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "James Michael Morrissey, EVP at Incyte (NASDAQ:INCY), reported acquisition of company stock options on July 27, according to a new SEC filing.\nWhat Happened: Uncovered in a Form 4 filing on Monday with the U.S.",
                "category": "company",
                "datetime": 1785236444,
                "headline": "James Michael Morrissey Expands Holdings With $54K Incyte Stock Options Acquisition"
              },
              {
                "id": 141041897,
                "url": "https://finnhub.io/api/news?id=32ab29909cba625ffb15085d0d5c96aeb1a13aba9148a5a5c07b9ef9e1684be5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "WILMINGTON, Del., July 28, 2026--Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates",
                "category": "company",
                "datetime": 1785236400,
                "headline": "Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates"
              },
              {
                "id": 141042267,
                "url": "https://finnhub.io/api/news?id=8eb48457e30ed759574902fad91ecc34d75054fa92fff08f027b6ddf02e62c26",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1329696857/image_1329696857.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Incyte Corporation stock hits a 52-week high on latarcibart and strong Opzelura/Zynyz sales, but valuation & Iclusig demand drive a Hold. Click for an INCY update.",
                "category": "company",
                "datetime": 1785231217,
                "headline": "Incyte: From Buy To Hold After A 93% Rally (Rating Downgrade)"
              },
              {
                "id": 141045517,
                "url": "https://finnhub.io/api/news?id=0e144d572c44e6dd35db0b4ad9192f81b8967aff5437052626aaa80b900565f9",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/28/Servicenow-Office-Building-At-Their-Head.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "ServiceNow shares rose 6.9% to settle at $105.56 during the session, while Meta shares fell 0.2% to close at $593.87 on Monday.",
                "category": "company",
                "datetime": 1785226718,
                "headline": "ServiceNow, Meta, eBay And A Health Care Stock On CNBC’s ‘Final Trades’"
              },
              {
                "id": 141048640,
                "url": "https://finnhub.io/api/news?id=49a358e634e174f6a43f4be58a48b5abcc7cd8bc78e77527abf5ce0adf1233f0",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Incyte (NASDAQ:INCY) reported quarterly earnings of $3.09 per share which beat the analyst consensus estimate of $2.12 by 45.75 percent. This is a 96.82 percent increase over earnings of $1.57 per share from the same",
                "category": "company",
                "datetime": 1785222171,
                "headline": "Incyte Q2 Adj. EPS $3.09 Beats $2.12 Estimate, Sales $1.663B Beat $1.460B Estimate"
              },
              {
                "id": 141048641,
                "url": "https://finnhub.io/api/news?id=2464e6d7fb6f48df07bacaf57abaf7b834d6343bdac34e55985cb7be19debe3b",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Incyte (NASDAQ:INCY) raises FY2026 sales outlook from $4.770 billion-$4.940 billion to $5.130 billion-$5.260 billion vs $5.712 billion estimate.",
                "category": "company",
                "datetime": 1785222058,
                "headline": "Incyte Raises FY2026 Sales Guidance from $4.770B-$4.940B to $5.130B-$5.260B vs $5.712B Est"
              },
              {
                "id": 141031220,
                "url": "https://finnhub.io/api/news?id=2d9b5d3986d187fb5197c5ef9b0edab80e70e9a9efcc6abde9508b72f0a279da",
                "image": "https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "INCY stock shows a perfect technical breakout setup with a 10/10 Technical Rating and 9/10 Setup Quality, featuring a bull flag pattern and strong momentum.",
                "category": "company",
                "datetime": 1785140441,
                "headline": "INCYTE CORP (NASDAQ:INCY) Exhibits Perfect Technical Breakout Setup with Strong Ratings"
              },
              {
                "id": 141030717,
                "url": "https://finnhub.io/api/news?id=ad4f54ff1118d2b454e581ed1dfde278d76cb2e6b8f5c0deb0f11f897d8b3228",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results this Tuesday before the bell. Here’s what to look for.",
                "category": "company",
                "datetime": 1785126542,
                "headline": "What To Expect From Incyte’s (INCY) Q2 Earnings"
              },
              {
                "id": 141021094,
                "url": "https://finnhub.io/api/news?id=3dc13cfc64224bb859f64f02def1e1e27d7a4e954ab5830cfdac7e3136c8c299",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (NasdaqGS:INCY) reported full safety and efficacy results from its Phase 1/2 study of latarcibart, a once monthly subcutaneous therapy for von Willebrand disease. The company announced the acquisition of VGA039 (latarcibart) through the purchase of Vega Therapeutics to support further development. Latarcibart carries breakthrough, fast track, orphan drug, and rare pediatric disease designations. For investors tracking Incyte, this update sits at the intersection of rare disease drug...",
                "category": "company",
                "datetime": 1785028292,
                "headline": "Incyte (INCY) Reports Full Latarcibart Data And Buys Vega Therapeutics"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 61,
            "discarded_article_count": 44
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 20.9,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 2.2,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.2,
            "vcp_reason": "波幅收縮(17.2%→9.7%)；跌縮量(近10日6日)；站上MA50；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 3,
              "vol_ref": 1733596.6666666667,
              "down_days": 6,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 1249830,
              "avg_vol_20": 1886935,
              "avg_vol_30": 1733596.6666666667,
              "range_pct_10": 0.09659268521412931,
              "range_pct_20": 0.13152555486089404,
              "range_pct_30": 0.1722414035636136,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.7209462408595617,
              "dist_to_20d_high": 0.03499253129769752,
              "down_shrink_days": 6,
              "breakout_level_20d": 132.60001,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.5607982936486866
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.4,
            "details": {
              "atrPct": 2.6453579243513596,
              "turnoverUsdM": 71.48626156,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.INCY",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 121.19,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 0.5,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 5.3,
            "take_profit_price": 135.0347,
            "target_multiplier": 1.9,
            "technical_strength": 1.65,
            "take_profit_percent": 5.5
          },
          "positionPoints": 1.4,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.290715848702719,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 3.385,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.65
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 105.25
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.0796
    },
    "kdj": {
      "d": 74.75,
      "j": 93.21,
      "k": 80.9,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "入貨中",
      "score": 8,
      "value": 61.75
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 15655861,
      "recentSlope": 48666.1,
      "previousSlope": -908200
    },
    "rsi": 71.47,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 118.3024,
      "position": "SAR喺價下",
      "distancePct": 7.55,
      "previousTrend": "上升"
    },
    "ma50": 116.6018,
    "macd": {
      "macd": 2.9551407496407336,
      "trend": "強烈看漲",
      "signal": 2.559275590226056,
      "histogram": 0.3958651594146776
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 123.3533,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 6
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.31,
      "score": 2,
      "avgVolume": 1778423,
      "currentVolume": 558661
    },
    "derived": {
      "ma20": 122.9905,
      "ma50": 116.6018,
      "prevClose": 127.81,
      "avgVolume10": 1170456,
      "avgVolume20": 1778423,
      "changePercent": 0.12,
      "avgVolumeForScore": 1778423
    },
    "ma_cross": {
      "ma20": 122.9905,
      "ma50": 116.6018,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 122.536,
      "prevMa50": 116.1992,
      "spreadPct": 5.48,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 115.7506,
      "upper": 130.2304,
      "position": "上半部"
    },
    "rsi_short": 87.64,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.31
    }
  }
}

{
  "close": 127.96,
  "volume": 558661,
  "changePercent": 0.12
}